Intrexon Corporation (XON) Stock Rating Lowered by Zacks Investment Research

Intrexon Corporation (NYSE:XON) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.

According to Zacks, “Intrexon depends largely on ECCs and license and collaboration deals for revenues and any unfavorable outcome from the development of these could be a major setback and hurt its prospects too. Furthermore, shares of the company have underperformed the Medical Services industry in the last one year. However, the company's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are also positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures. Additionally, it announced the formation of a wholly-owned subsidiary-Precigen, Inc. as part of its structural alternatives so that it can take better decisions of its health business. Estimates have been mixed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters.”

Other research analysts have also issued research reports about the company. BidaskClub raised Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the company a “buy” rating in a research report on Monday, August 7th. JMP Securities reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, Griffin Securities reaffirmed a “buy” rating and set a $55.00 price objective on shares of Intrexon Corporation in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $43.20.

Intrexon Corporation (XON) opened at 17.99 on Monday. The company’s 50 day moving average price is $19.19 and its 200 day moving average price is $21.07. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90. The stock’s market cap is $2.17 billion.

Intrexon Corporation (NYSE:XON) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. During the same quarter last year, the company earned ($0.42) EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2017/10/18/intrexon-corporation-xon-stock-rating-lowered-by-zacks-investment-research.html.

In related news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average price of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dean J. Mitchell acquired 5,000 shares of Intrexon Corporation stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average cost of $18.33 per share, with a total value of $91,650.00. Following the transaction, the director now owns 18,103 shares in the company, valued at $331,827.99. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 144,569 shares of company stock valued at $2,719,429. 56.30% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of XON. Tower Research Capital LLC TRC boosted its stake in Intrexon Corporation by 2,031.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Intrexon Corporation during the 1st quarter valued at $164,000. Federated Investors Inc. PA purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $172,000. Cullinan Associates Inc. purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $201,000. Finally, John G Ullman & Associates Inc. purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $212,000. Institutional investors and hedge funds own 82.11% of the company’s stock.

According to Zacks, “Intrexon depends largely on ECCs and license and collaboration deals for revenues and any unfavorable outcome from the development of these could be a major setback and hurt its prospects too. Furthermore, shares of the company have underperformed the Medical Services industry in the last one year. However, the company's expanding portfolio of technologies has enabled it to develop a robust pipeline of candidates targeting a broad range of diseases including cancer and others. We are also positive on Intrexon’s efforts to expand through acquisitions, exclusive channel collaborations (ECCs) and joint ventures. Additionally, it announced the formation of a wholly-owned subsidiary-Precigen, Inc. as part of its structural alternatives so that it can take better decisions of its health business. Estimates have been mixed ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters.”

Other research analysts have also issued research reports about the company. BidaskClub raised Intrexon Corporation from a “sell” rating to a “hold” rating in a research report on Thursday, June 22nd. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the company a “buy” rating in a research report on Monday, August 7th. JMP Securities reaffirmed an “outperform” rating and set a $42.00 price objective on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, Griffin Securities reaffirmed a “buy” rating and set a $55.00 price objective on shares of Intrexon Corporation in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $43.20.

Intrexon Corporation (XON) opened at 17.99 on Monday. The company’s 50 day moving average price is $19.19 and its 200 day moving average price is $21.07. Intrexon Corporation has a 12 month low of $17.03 and a 12 month high of $32.90. The stock’s market cap is $2.17 billion.

Intrexon Corporation (NYSE:XON) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 19.08% and a negative net margin of 60.63%. The company had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. During the same quarter last year, the company earned ($0.42) EPS. The firm’s revenue for the quarter was up 3.6% on a year-over-year basis. Equities analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://ledgergazette.com/2017/10/18/intrexon-corporation-xon-stock-rating-lowered-by-zacks-investment-research.html.

In related news, Director Robert B. Shapiro acquired 2,850 shares of Intrexon Corporation stock in a transaction that occurred on Tuesday, August 22nd. The stock was bought at an average price of $17.50 per share, with a total value of $49,875.00. Following the transaction, the director now directly owns 43,157 shares in the company, valued at $755,247.50. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Dean J. Mitchell acquired 5,000 shares of Intrexon Corporation stock in a transaction that occurred on Friday, August 11th. The shares were bought at an average cost of $18.33 per share, with a total value of $91,650.00. Following the transaction, the director now owns 18,103 shares in the company, valued at $331,827.99. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 144,569 shares of company stock valued at $2,719,429. 56.30% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently modified their holdings of XON. Tower Research Capital LLC TRC boosted its stake in Intrexon Corporation by 2,031.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after purchasing an additional 4,937 shares during the last quarter. SG Americas Securities LLC purchased a new stake in Intrexon Corporation during the 1st quarter valued at $164,000. Federated Investors Inc. PA purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $172,000. Cullinan Associates Inc. purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $201,000. Finally, John G Ullman & Associates Inc. purchased a new stake in Intrexon Corporation during the 2nd quarter valued at $212,000. Institutional investors and hedge funds own 82.11% of the company’s stock.

Intrexon Corporation Company Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Analyst Recommendations for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply